帕罗西汀联合小剂量硫必利治疗躯体形式障碍的对照研究

目的探讨帕罗西汀联合小剂量硫必利治疗躯体形式障碍的疗效。方法将躯体形式障碍患者分为两组：研究组（帕罗西汀联合小剂量硫必利）和对照组（单用帕罗西汀联合安慰剂）,以汉密尔顿抑郁量表（HAMD）的减分率评定药物的起效时间和症状改善时间,分别在治疗前、治疗第2、4及8周进行症状自评量表（SCL-90）的检测,采用副反应量表（TESS）评估药物安全性。结果①研究组在起效时间和症状改善时间均比对照组快;②治疗第2、4周时两组在躯体化、焦虑、抑郁及偏执分值上差异有统计学意义,而治疗第8周时SCL-90除偏执因子分外,两组比较无显著差异;③两组在不良反应方面无显著差异。结论帕罗西汀联合小剂量硫必利治疗躯体形式障碍的疗效较单用帕罗西汀疗效更佳。

Case-control study of treating somatoform disorders by Paroxetine hydrochloride combined with small dosage of Tiapride

Objective To explore the efficiency of treating somatoform disorders by Paroxetine hydrochloride combined with small dosage of Tiapride.Methods Somatoform disorders patients were assigned into two groups：the study group who took Paroxetine hydrochloride combined with small dosage of Tiapride and the control group who took Paroxetine hydrochloride single.The time of efficacy and improvement were evaluated by the reduced rate of Hamilton Rating Scale for Depression（HAMD）,the self-report symptom inventory（SCL-90） was detected after the second,the fourth and the eighth week,safety was evaluated by Treatment Emergent Symptom Scale（TESS）.Results ①The time of efficacy and improvement was shorter in study group than that in control group.②Compared with factors of SCL-90 in two groups after the second and the fourth week treatment,the significant difference was observed in scores of somatoform,anxiety,depression,paranoid.There was no significant difference in factors of SCL-90 except paranoid after the eighth week treatment.③No significant difference of side-effects was observed in two groups.Conclusion It was indicated that the efficacy to choice of Paroxetine hydrochloride combined with small dosage of Tiapride could be better than Paroxetine hydrochloride only when treating clinically somatoform disorders.